Introduction

There is a clear relationship between the degree of hyperglycemia and the severity of periodontitis. The possible mechanisms by which DM might affect the periodontium are increased counts of subgingival pathogenic bacteria such as Capnocytophaga, anaerobic vibrios, Actinomyces species, Porphyromonas gingivalis, Prevotella intermedia, and Aggregatibacter actinomycetemcomitans. Neutrophil impairment leads to increased susceptibility to periodontitis in people with diabetes. Hyperglycemia induces decreased chemotaxis, phagocytosis, and intracellular bacterial activity in diabetics. Collagen from diabetes patients has been reported to be more insoluble and resistant to digestion, directly impairing degradation, and remodeling. The basement membrane protein undergoes non-enzymatic glycosylation when subjected to hyperglycemic conditions. The gingival capillaries of diabetic patients have greater basement membrane thickness.

Alveolar bone loss is a hallmark of periodontitis progression, and its prevention is a crucial clinical challenge in periodontal disease treatment. Periodontal treatment aims to eliminate biofilms, remove microbial deposits from the root surface, decrease tissue destruction, and regenerate lost tissues.

Bone grafts are frequently used in oral surgeries to facilitate or promote bone regeneration, provide mechanical support for the membrane, fill bone defects, increase bone augmentation, and stabilize blood clots. Many bone graft materials are available to resolve bone defects, including autografts, allografts as freeze-dried bone from human donors, xenografts from animals or plants, and alloplasts, which are synthetic bone substitutes as polymers, bioactive glass, hydroxyapatite, and metal-substituted hydroxyapatite.
hydroxyapatite, and beta-tricalcium phosphate. All these materials are not perfect substitutes for bones and have some advantages and disadvantages.\(^4\)

A new material, referred to as strontium ranelate (SR), is used to replace bone loss. This material is composed of two atoms of stable strontium combined with ranelic acid, which serves as a carrier. Strontium ranelate, which is used for osteoporosis treatment, is the first drug to exhibit a dual action on bone metabolism. It combines the antiresorptive effects by inhibiting osteoclastic differentiation and activity with an anabolic effect on bone formation by stimulating osteoblastic differentiation, activity, and collagen synthesis.\(^5\)

Hydroxyapatite (HA) is a commonly used bone graft material and is a well-documented biomaterial known for its osteoconductivity.\(^6\) Iron oxide nanoparticles are currently used for these applications; however, there are concerns over acute toxicity. Since HA is biocompatible and biodegradable for dental and hard tissue grafts, magnetic HA application will mitigate these concerns.\(^7\) Besides, iron oxide nanoparticles can play a positive role in enhancing the magnetic properties of the product. These particles have to be integrated into the structure of hydroxyapatite particles.\(^8\)

Conventional radiographs generate 2D images in which the roots are superimposed on the bone; thus, bone changes, such as furcation involvement and buccal and lingual bone changes, are difficult to observe.\(^9\) The cone-beam computed tomography (CBCT) has been used to visualize the interproximal defects and buccal and lingual bone defects for diagnosing dehiscence and fenestration defects for evaluating diagnostic and treatment outcomes of periodontitis, evaluating postsurgical results of regenerative periodontal therapy, measuring alveolar bone density, and assessing the healing process after graft placement in periodontology.\(^10\)

This study aimed to compare SR and metal-substituted hydroxyapatite (MSHA) bone graft materials for treating chronic periodontitis in patients with diabetes mellitus.

### Methods

#### Patient Selection

This study included 20 sites in controlled type II diabetic patients with severe chronic periodontitis selected from the Periodontology Clinic, Faculty of Dentistry, Mansoura University. The patients’ ages ranged from 35 to 55 years, their consent was taken, and all the procedures were explained before treatment.

All the procedures followed the ethical standards of the Committee on Human Experimentation (institutional and national) and the Helsinki Declaration, as revised in 2013. The study protocol was approved by the relevant Research Ethics Committee.

#### Inclusion Criteria

The selected patients fulfilled the following criteria:

- At least 20 teeth remaining in the oral cavity
- Pocket probing depth (PPD) ≥5 mm
- Clinical attachment level (CAL) ≥5 mm
- Vertical bone loss on radiographic examination
- Patients who are able to maintain good oral hygiene
- Glycosylated hemoglobin (HbA1C) in controlled diabetics ≤7%

#### Exclusion Criteria

- History of systemic diseases other than type II diabetes
- Smoking
- Pregnant or lactating women
- Previous treatment of periodontal diseases in the last six months

#### Materials

1. **Osteostatin (Strontium Ranelate)**

Bone graft material for dental use was manufactured in the Arab Republic of Egypt (ARE) and approved by the Solicitors Regulation Authority (SRA). It is composed of two atoms of stable strontium combined with ranelic acid, which acts as a carrier.

2. **Metal Substituted Hydroxyapatite**

Pure HA nanoparticles doped with Mn\(^{2+}\) and Fe\(^{3+}\) ions were synthesized using the wet chemical method (WCM). The samples were formed by different spectroscopic techniques in the Department of Physics, Faculty of Science at Mansoura University.

3. **Gengigel**

Gengigel was manufactured by Ricerfarma in European Union. It is composed of 0.2% hyaluronic acid and 7.5% xylitol (extracted from birch and beech trees).

#### The Clinical Study Design

1. **Phase I Therapy**

All the patients were subjected to full-mouth scaling and root planing (SRP) using hand instruments and ultrasonic and proper oral hygiene instructions. In addition, an occlusal adjustment was performed if signs of trauma were evident. One month after phase I therapy, all the patients were evaluated to ensure the surgical procedure’s local fitness. All the patients performed a glycosylated hemoglobin analysis before periodontal surgery.

2. **Patient Groups**

After phase I therapy, a randomized split-mouth
study was used on the selected patients to receive one of the two proposed treatments on one side and the other treatment on the contralateral side. This randomization was achieved by a computer-generated table.

**First, proposed treatment (group 1):** It was applied in 10 randomized sides and included a surgical flap with a mix of 1 g of SR with Gengigel.

**Second, proposed treatment (group 2):** It was applied in 10 contralateral sides and included a surgical flap with a mix of 1 g of MSHA bone graft materials with Gengigel.

3. **Clinical Assessment**

A proper case history was obtained from each patient considering the history of the present chief complaint, onset and duration of the patients' periodontal manifestations, and any past dental treatment. Each patient was thoroughly examined clinically to assess the gingival tissue condition in terms of color, size, texture, and contour. Clinical evaluation was performed using the following clinical parameters:

- **Plaque index (PI):** at the baseline and after 1, 3, and 6 months
- **Gingival index (GI):** at the baseline and after 1, 3, and 6 months
- **Probing pocket depth (PPD):** at the baseline, 3, and 6 months only
- **Clinical attachment level (CAL):** at the baseline, 3, and 6 months, only

4. **Radiographic Examination**

The bone level of teeth indicated in the surgery was measured by cone-beam images (i-CAT Next Generation Machine, Imaging Sciences International, Hatfield, PA, USA). Cone-beam CT was taken at baseline and six months after surgery for measuring changes in the bone level of the indicated bone defect site.

- **Preoperative bone defect (at baseline):** was measured as the distance from the cementoenamel junction (CEJ) to the bone defect base.
- **Postoperative bone defect (after six months):** was measured as the distance from the CEJ to the base of the bone formation.
- **Postoperative bone fill (bone gain after six months):** was deducted by subtracting the postoperative bone defect from the preoperative bone defect.

5. **The Surgical Phase**

After phase I therapy, and adequate local anesthesia, buccal and lingual intrasulcular incisions were made using Bard-Parker blade #15, and a full-thickness flap was reflected to expose the intrabony defects, with care to preserve the interdental papilla. After debridement of the osseous defects, the root surfac-}

es were thoroughly scaled and planed with Gracey curettes. Then according to the selected treatment modality, either SR (Osteostatine) or MSHA was mixed with 2–4 drops of hyaluronic acid (Gengigel) to achieve a putty consistency that was carried by a spoon-like instrument into the defect site until filled, and then condensed gently with a sterile smooth amalgam condenser. Suturing was carried out with 0.3 nonresorbable sutures (Figures 1 and 2).

6. **Postoperative Care**

1. Amoxicillin (500 mg) was prescribed twice daily for seven days.
2. Non-steroidal anti-inflammatory drug (NSAID) was prescribed every eight hours for two days to control postoperative discomfort (Ibrofen, 600 mg).
3. A soft diet and a mouth rinse with 0.12% chlorhexidine solution were recommended twice daily for 10 days.
4. The patient was instructed to avoid hard and spicy food post-surgically.
5. Two weeks after the operation, the sutures were removed, and all the patients were instructed to use a soft toothbrush for plaque control.
6. All the patients were recalled for professional prophylactic and plaque control procedures once every two weeks during the first month and once a month for six months.

**Statistical Analysis**

All the data were collected, tabulated, and statistically analyzed using SPSS 21. The difference between the two groups was analyzed using the independent sample (Student) t-test, and intergroup comparison was performed using a paired t-test. P-values<0.05 were considered statistically significant.

**Results**

The two treatment modalities showed a statistically significant reduction in PPD and CAL at three
and six months compared to the mean baseline value. Intergroup comparison showed that group 1 had significantly less PPD and CAL compared to group 2. Comparing the two sides by CBCT showed an increase of nearly 3.4 mm in the height of the alveolar bone on the group 1 (SR) side while the opposite side in group 2 (MSHA) showed a nearly 1.4 mm increase in the height of the alveolar bone (Tables 1 and 2) (Figures 3 and 4).

Discussion

As periodontal treatment’s critical problem is the difficulty in restoring the alveolar bone, regenerative therapy has found its way to improve periodontal therapy. Among these regenerative materials is SR, which has been used for the replacement of bone loss. Also, magnetic hydroxyapatite nanoparticles enable their use in numerous therapeutic applications in the field of regeneration. Hyaluronic acid plays a multifunctional role in periodontal tissue healing, aiding in periodontal disease treatment. Topical hyaluronic acid can be useful as an adjunctive treatment in gingivitis, chronic periodontitis, and during the postoperative period for implant and sinus lift procedures to induce faster healing and reduce the patients’ discomfort during the postoperative period.

Therefore, the present study was designed to compare SR (osteostatin) mixed with Gengigel and MSHA bone graft material mixed with Gengigel when used as an adjunct in open flap debridement in the treatment of bone loss due to periodontal disease in controlled diabetic patients (glycosylated hemoglobin [HbA1C] ≤7%).

This study was designed as a split-mouth investigation to facilitate the comparison of the two treatment procedures by eliminating patient-specific characteristics that might have an impact on the results of regenerative surgeries. The split-mouth design was considered adequate for evaluating regenerative procedures in a recent systematic review. Wenzel et al reported no increase in bone fill between 6 and 12 months, which might support why the 6-month radiographic analysis was preferred in the present study.

Mol and Balasundaram compared the image quality between CBCT and conventional radiograph in assessing alveolar bone levels. They found that CBCT provided superior diagnostic accuracy and quantitative information on periodontal bone levels in three dimensions than conventional radiography.
In the present study, all the treatment modalities were well tolerated by the periodontal tissues of all the subjects who showed no signs of inflammation or postoperative pain. Also, no adverse reactions, such as allergies or abscesses, were observed in any patients. The present study showed a reduction in the mean PI and GI scores during the study period in all the groups compared to baseline values. The reduction in PI and GI in both groups might be attributed to SRP and adequate oral hygiene maintenance, instructed to each patient. Regarding the PI and GI, at all evaluation periods, the t-test showed a statistically insignificant difference between the two treated groups, and it can be explained that the two treatments were performed in the same patient with the same oral hygiene and environment.

In the SR group, the reduction in GI was consistent with that reported by Nunes et al., who found that SR has an anti-inflammatory effect by reducing the release of cytokine tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β).

The reduction of GI in both groups can be attributed to the addition of Gengigel to the SR and metal-substituted hydroxyapatite. Hyaluronic acid has many important physiological and biological functions, such as the regulation of inflammation, enhanced cell migration, proliferation, differentiation, angiogenesis, osteoconduction, carrier function, bacteriostatic function, and healing with less scarring. A clinical trial explored the utility of hyaluronic acid anti-inflammatory, anti-edematous, and anti-bacterial effects in treating periodontal disease. Therefore, hyaluronic acid has been employed in the treatment of gingivitis and periodontal pockets.

PPD and CAL results revealed a significant reduction in both treatment modalities at 3- and 6-month evaluation periods compared to baseline. At 3- and 6-month evaluation periods, the t-test showed a significant reduction in PPD and CAL between the two treated groups. Using an image analysis program for CBCT, there was a statistically significant reduction in VBL in both groups compared to baseline values.

### Table 1. Mean values of plaque index (PI), gingival index (GI), probing pocket depth (PPD) in mm, clinical attachment level (CAL) in mm, among the study groups at baseline, 3 and 6 months and after treatment

| Variable | Groups/Time | Group I n = 10 mean ± SD | Group II n = 10 mean ± SD | P-value, independent samples t-test |
|----------|-------------|---------------------------|---------------------------|-----------------------------------|
| PI       | Baseline (1) | 2.42±0.42                 | 2.55±0.43                 | 0.647 *                             |
|          | 1 month (2)  | 0.77±0.27                 | 0.87±0.35                 | 0.790 *                             |
|          | 3 months (3) | 0.65±0.33                 | 0.82±0.28                 | 1.24±0.9                             |
|          | 6 months (4) | 0.67±0.23                 | 0.85±0.31                 | 1.40±0.9                             |
| Paired samples t-test | 0.0001 | 1 vs 2 & 3 & 4 *** | 0.0001 | 1 vs 2 & 3 & 4 *** |
| GI       | Baseline (1) | 2.30±0.30                 | 2.28±0.20                 | 0.129 *                             |
|          | 1 month (2)  | 0.60±0.17                 | 0.47±0.27                 | 1.24±0.9                             |
|          | 3 months (3) | 0.67±0.12                 | 0.52±0.24                 | 1.71±0.9                             |
|          | 6 months (4) | 0.67±0.20                 | 0.80±0.22                 | 1.28±0.9                             |
| Paired samples t-test | 0.0001 | 1 vs 2 & 3 & 4 *** | 0.0001 | 1 vs 2 & 3 & 4 *** |
| PPD      | Baseline (1) | 5.80±0.63                 | 6.00±0.66                 | 0.68±0.6                             |
|          | 3 months (2) | 2.65±0.47                 | 3.40±0.65                 | 2.93±0.6                             |
|          | 6 months (3) | 2.40±0.51                 | 3.10±0.56                 | 2.85±0.6                             |
| Paired samples t-test | 0.0001 | 1 vs 2 & 3 & 4 *** | 0.0001 | 1 vs 2 & 3 & 4 *** |
| CAL      | Baseline (1) | 5.05±0.49                 | 5.50±0.52                 | 1.96±0.6                             |
|          | 3 months (2) | 2.40±0.45                 | 2.95±0.49                 | 2.56±0.4                             |
|          | 6 months (3) | 2.10±0.31                 | 2.80±0.42                 | 4.20±0.4                             |
| Paired samples t-test | 0.0001 | 1 vs 2 & 3 & 4 *** | 0.0001 | 1 vs 2 & 3 & 4 *** |

*Significant change over time within group compared with baseline value (Significance: *P<0.05. **P<0.01, ***P<0.001 ns = not significant).†Significant difference between the two groups at different follow-up periods (P<0.05).

Group I = Patients treated with OFD with strontium ranelate bone graft material

Group II = Patients treated with OFD with metal substituted hydroxyapatite bone graft material
At baseline, there was no statistically significant difference in the mean VBL between the two groups; however, at the 6-month postoperative interval, there was a statistically significant reduction in the two groups. Regarding the BG, there was a significant increase in BG in the SR group (3.4 mm bone gain) compared to the MSHA group (1.4 mm bone gain).

This result is consistent with Ammann et al., who found that rats treated with SR over two years exhibited increased trabecular and cortical bone volumes and trabecular number and thickness. These findings were contributed to increasing alkaline phosphatase activity and IGF-1. Ammann et al. demonstrated that SR treatment could positively influence intrinsic bone tissue quality.

In group 2, the reduction in PPD, CAL, and bone gain was consistent with a previous report by Kasaj et al. on the clinical efficacy of NcHA paste in intrabony defects, indicating PPD and CAL reduction and bone gain. Schwarz et al. evaluated the healing of intrabony peri-implantitis defects following the application of two types of treatment, a NcHA or a bovine-derived xenograft combined with a collagen membrane (BDX1BG). Postoperative wound healing revealed that NHA compromised the initial adhesion of the mucoperiosteal flaps in all patients.

This study was consistent with Bhardwaj et al., who evaluated the efficacy of an indigenously prepared zinc incorporated nanohydroxyapatite (ZINH) bone graft in the treatment of intrabony defects. A split-mouth study, which consisted of 11 systemically healthy subjects with 45 sites, randomly used ZINH or nano-HA alone. Statistically significant improvements in all the clinical parameters were seen in the test sites at 12 months. They concluded that ZINH bone graft could be considered a prospective bone regenerative material.

Li et al. concluded that Mn-substituted hydroxyapatites exhibited a remarkably beneficial effect on bone cells, and it has been shown that a relatively high Mn²⁺ doping concentration promotes osteocalcin production. Also, Mn-substituted hydroxyapatites were able to support human osteoblast differentiation, proliferation, and metabolism activation. Hence, the adhesion of osteoblasts to Mn-substituted hydroxyapatites is a crucial step for subsequent osteoblast functions. Mn²⁺ ions increase ligand binding affinity, integrating and activating cell adhesion.

Wu et al. reported that iron (Fe²⁺) substituted HA nanoparticles were superparamagnetic and exhibited good biocompatibility. It has also been reported that iron compounds can promote the nucleation of apatites and adsorption of salivary calcium and phosphate ions, favoring minerals’ replacement.

Conclusion

Strontium ranelate and MSHA bone graft material exhibited good results and an ability to augment the bone, reducing the pocket depth, improving clinical attachment levels, and promoting defect fill. However, it should be noted that the effect of MSHA was less than the strontium ranelate bone graft material. Cone-beam CT provides high-resolution images that can be used to gather diagnostic and quantitative information on periodontal bone health. The 3D images are ideal for evaluating the intrabony defects and assessing the treatment outcomes.

Recommendations

Further studies are required to investigate larger numbers of patients with different types of periodontal defects and more extended periods of follow up to evaluate the efficiency of strontium ranelate bone graft and metal-substituted hydroxyapatite in improving the periodontal intrabony defects in chronic periodontitis patients.

Acknowledgments

A special thanks and great gratitude to Dr Omar Khashaba, who might have passed away this year, but his memory will never leave us for his continuous support and motivation that have always been a beacon guiding us towards success, and we will never forget all his contributions no matter how many years pass. Although Dr Omar is no longer with us, his instructions and guidelines will always be, and hopefully, we will continue to follow them as long as possible. We love you and miss you so much, Dr. Omar Khashaba.

Authors’ contributions

KOH: This author was responsible for the study’s concept and design and critically revised the manuscript for important intellectual content. AAA: This author did the
study’s clinical work, including collecting the patients and performing the surgeries. This author conducted a conception and design along with analysis and interpretation of data. EEA: This author undertook the collection and collection of data. Furthermore, this author revised and approved the manuscript to be published. MB: This author undertook the acquisition and collection of radiologic data.

**Funding**

There was no funding support for the study

**Competing interests**

The authors declare no conflict of interests.

**Ethics approval**

Ethics Committee number: 03111218.

**References**

1. Preshaw PM, Alba AI, Herrera D, Jepsen S, Konstantinidis A, Makrilakis K et al. Periodontitis and diabetes: a two-way relationship. Diabetologia 2011;55:21–31. doi: 10.1007/s00125-011-2342-y

2. Daniel R, Gokulanathan S, Shamugasundaram N, Lakshmigandhan M, Kavin T. Diabetes and periodontal disease. Journal of Pharmacy and Biomedical Sciences 2012;4:S280-S282. doi: 10.4103/0975-7406.100251

3. Hienz SA, Paliwal S, Ivanovski S. Mechanisms of Bone Resorption in Periodontitis. J Immunol Res. 2015;2015:615486. doi: 10.1155/2015/615486

4. Hassan K. and Aalagi A. A comparative study of bovine bone used alone and in combination with transforming growth factor-beta for the treatment of periodontal osseous defects in humans. Saudi Journal of Medicine and Medical Sciences, 2015;3:33.

5. Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001; 69: 121-9. doi: 10.1007/s002230010055

6. Zhou H, Lee J. Nanoscale hydroxyapatite particles for bone tissue engineering. Acta Biomaterialia 2011;7:2769-2781. doi: 10.1016/j.actbio.2011.03.019

7. Søensen SJ, Himmelreich U, Nuytten N and Cuypers MD. Cytotoxic effects of iron oxide nanoparticles and implications for safety in cell labelling. Biomaterials 2011;32:195-205. doi: 10.1016/j.biomaterials.2010.08.075

8. Neuwelt EA, Várallyay CG, Manninger S, Solymosi D, Haluska M, Hunt MA, et al. The potential of ferumoxytrol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy. A pilot study. Neurosurgery 2007;60:601-12. doi: 10.1227/01.NEU.0000255350.71706.37

9. Jeffcoat MK, Wang I-C, Reddy MS. Radiographic diagnosis in periodontics. Periodontology 2000;1995;7:54–68. doi: 10.1111/j.1600-0765.1995.tb00368.x

10. Songa VM. Accuracy of Cone Beam Computed Tomography in Diagnosis and Treatment Planning of Periodontal Bone Defects: A Case Report. Journal of Clinical and Diagnostic Research 2014;8: ZD23–ZD25. doi: 10.7860/JCRD/2014/11165.5348

11. Silness P, Løe H. Periodontal disease in pregnancy I. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand 1964;112-35. doi: 10.3109/00016356308999368

12. Loe H, Silness J. Periodontal disease in pregnancy: Prevalence and severity. Acta Odontol Scand 1963;53:31. doi: 10.3109/00016356309011240

13. Ramfjord SP. Indices for prevalence and incidences of periodontal Disease, J Periodontology 1959;30:5-9.

14. El-Damrawi G, Kamal H, Dowidar H, Dawood A. Microstructure and in vitro Bioactivity of Metal Substituted Hydroxyapatite. British Journal of Applied Science & Technology 2016;15:1-12.

15. Casale M, Mofta A, Vella P, Sabatino L, Capuano F, Salvinelli B, et al. Hyaluronic acid: Perspectives in dentistry. A systematic review. International Journal of Immunopathology and Pharmacology 2010;26:572-582. doi: 10.1177/0394630210652906

16. Hujol JP, Moulton LH. Evaluation of test statistics in split-mouth clinical trials. J Periodontal Res. 1988; 23:378-80. doi: 10.1111/j.1600-0765.1988.tb01616.x

17. Needleman I, Tucker R, Giedrys-Leeper E, Worthington H. Guided tissue regeneration for periodontal intrabony defects - A Cochrane Systematic Review. Periodontol 2000. 2005;37:106–23. doi: 10.1111/j.1600-0757.2004.37101.x

18. Wenzel A, Warrer K, Karring T. Digital subtraction radiography in assessing bone changes in periodontal defects following guided tissue regeneration. J Clin Periodontol. 1992;19:208-13. doi: 10.1111/j.1600-051x.1992.tb00641.x

19. Mol A, Balusundaram A. In vitro cone beam computed tomography imaging of periodontal bone. Dentomaxillofac Radiol 2008;37:319-324. doi: 10.1259/dmf/r26475758

20. Nunes RM, Martins MR, da Silva Junior FS, Leite ACM, Girão VC, Cunha FQ, et al. Strontium ranelate analgesia in arthritis models is associated to decreased cytokine release and opioid-dependent mechanisms. Inflamm Res 2015;64:781-787.

21. Shuborna NS, Chaiyasamut T, Sakdajeuyont W, Vorakulipapat C, Royvanakarn M, Wongrisichat N. Generation of Novel Hyaluronic Acid Biomaterials for Study of Pain in Third Molar Intervention: A Review J Dent Anesth Pain Med,2019;19:11-19. doi: 10.17245/jdpm.2019.19.11

22. Ammann P, Shen V, Robin B, Mauras Y, Bonjour JP, Rizzoli R. Strontium Ranelate Improves Bone Resistance by Increasing Bone Mass and Improving Architecture in Intact Female Rats. J Bone Miner Res 2012;19:20. doi: 10.1359/JBMR.040906

23. Kasaj A, Röhrig B, Zafiropoulos GG, Willershausen B. Clinical evaluation of nanocrystalline hydroxyapatite paste in the treatment of human periodontal bony defects – A randomized controlled clinical trial: 6month results. J Periodontol 2008;79:394-400. doi: 10.1902/jop.2008.070378

24. Schwarz F, Bieling K, Latz T, Nuesy E, Becker J. Healing of intrabony perimplantitis defects following application of a nanocrystalline hydroxyapatite (Ostim) or a bovine-derived xenograft (BioOss) in combination with a collagen membrane (BioGide). A case series. J Clin Periodontol 2006;33:491-9. doi: 10.1111/j.1600-065X.2006.00936.x

25. Bhardwaj VA, PC Deepika, Basavarajiah S. Zinc Incorporated Nano Hydroxyapatite: A Novel Bone Graft Used for Regeneration of Intrabony Defects. Contemp Clin Dent 2018; 9:427-433. doi: 10.4103/ccd.ccd_192_18

26. Li Y, Nan CT, Ooi CP, Iron (III) and manganese (II) substituted hydroxyapatite nanoparticles: Characterization and cytotoxicity analysis. Journal of Physics: Conference Series 2019;200:120524.

27. Wu HC, Wang TW, Sun JS, Wang WH, Lin FH. A novel biomagnetic nanoparticle based on hydroxyapatite. Nanotechnology 2007;18:165601-165610.